Four new hires get Taysha stock awards tied to 384,000 shares, plus rights to buy more.
Taysha Gene Therapies granted equity awards to four new employees on October 1, 2026, as an inducement for employment, as per Nasdaq Listing Rule 5635(c)(4). These awards include restricted stock units (RSUs) representing 384,000 common shares and an option to purchase 92,400 common shares. The RSUs vest in four equal annual installments, while the stock option vests 25% on the first anniversary and the remaining 75% monthly over 36 months, both contingent on continued service.
Wolfe Research Initiates Taysha Gene Therapies(TSHA.US) With Buy Rating
Wolfe Research has initiated coverage on Taysha Gene Therapies (TSHA.US) with a Buy rating. This indicates a positive outlook from the research firm regarding the company's stock performance.
Taysha Gene Therapies, Inc. launches webinar to advance patient-centered Rett syndrome trials
Taysha Gene Therapies, Inc. is promoting a webinar focused on advancing patient-centered clinical trials for Rett syndrome. The webinar, hosted by the Child Neurology Society and featuring Dr. Arthur Partikian, will discuss how natural history research can refine treatment expectations and prepare the community for new therapies. This initiative aligns with Taysha's broader efforts in engaging clinical and patient communities in rare diseases, following recent advancements like a commercial supply agreement with Catalent for TSHA-102 and a 6.7% stock increase after an earnings announcement.
New Taysha Gene Therapies hires receive 349,000-share stock grant
Taysha Gene Therapies (Nasdaq: TSHA) announced it granted 349,000 restricted stock units (RSUs) to three new employees on February 2, 2026, as an inducement award under its 2023 Inducement Plan. These RSUs will vest in four equal annual installments, contingent upon continued employment. This move aligns with Nasdaq Listing Rule 5635(c)(4) and is part of the company's strategy to attract and retain talent in the gene therapy sector.
TSHA-102 Rett Data, Expanded Catalent Deal And New Financing Might Change The Case For Investing In Taysha Gene Therapies (TSHA)
Taysha Gene Therapies (TSHA) recently reported Q2 2026 results with a net loss of US$46.64 million, but achieved a 100% responder rate in its pivotal TSHA-102 Rett syndrome trials. The company also expanded its manufacturing partnership with Catalent and secured US$230 million in financing, extending its cash runway to late 2028. These developments are expected to significantly reshape the investment outlook for Taysha, as it prepares for potential regulatory filing and commercialization of TSHA-102.
Taysha Gene Therapies (TSHA) Q2 2026 Earnings Call
Taysha Gene Therapies announced the completion of patient dosing in both the REVEAL pivotal and ASPIRE trials for TSHA-102, a gene therapy for Rett syndrome, with positive longer-term follow-up data showing consistent functional gains. The company has expanded its manufacturing partnership with Catalent and strengthened its financial position with a $230 million financing, extending its cash runway into the second half of 2028. Taysha anticipates reporting top-line data from the REVEAL trial's 6-month interim analysis and receiving FDA feedback on the BLA pathway in the first half of 2027.
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Consensus Recommendation of "Buy" from Brokerages
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received a consensus "Buy" recommendation from fourteen brokerages, with an average 12-month price target of $12.7692. Several analysts have recently increased their price targets for the stock. Despite missing its last quarterly EPS estimate, the company holds a market capitalization of $2.02 billion and analysts anticipate a -0.51 EPS for the current year.
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies (TSHA) completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, a gene therapy candidate for Rett syndrome, and is preparing for a potential biologics license application (BLA) submission. The company plans a six-month interim analysis of the REVEAL trial, which could accelerate its BLA filing. Despite a reported Grade 2 peripheral sensory neuropathy in one patient, the therapy has been generally well-tolerated, and manufacturing preparations for commercialization are underway.
RA Capital reports 9.99% TSHA stake in Taysha Gene Therapies (TSHA)
RA Capital Management and affiliated funds have filed an amended Schedule 13G, disclosing a beneficial ownership of 9.99% in Taysha Gene Therapies (TSHA) common stock as of June 30, 2026. This ownership includes common shares and a portion of pre-funded warrants, capped by a "Beneficial Ownership Blocker" at 9.99%. The filing indicates RA Capital maintains voting and dispositive power over these securities.
Morgan Stanley (TSHA holder) discloses 5.1% Taysha Gene Therapies stake in 13G/A
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC have reported a beneficial ownership of 16,244,339 shares, or 5.1%, of Taysha Gene Therapies, Inc. common stock as of June 30, 2026. This disclosure was made in an Amendment No. 2 to Schedule 13G filing. The filing details shared voting power over 16,067,509 shares and shared dispositive power over all 16,244,339 shares, with Morgan Stanley Capital Services LLC specifically reporting 5.0% ownership.
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies announced its second-quarter 2026 financial results, highlighting the completion of dosing in its REVEAL pivotal and ASPIRE trials for TSHA-102 in Rett syndrome. The company expects to report topline data from a 6-month interim analysis and receive FDA feedback on its Biologics License Application (BLA) submission pathway in the first half of 2027. Taysha also completed a $230 million follow-on offering, extending its cash runway into the second half of 2028, and expanded its manufacturing partnership with Catalent.
Taysha Gene Therapies (TSHA) Stock Trades At A Premium Despite A 232% Return
Taysha Gene Therapies (TSHA) has seen a significant 232% return over three years, yet its current valuation, particularly its Price-to-Book ratio of 9.8x against an industry average of 2.5x, suggests it trades at a premium. The company's valuation appears to already price in expectations for its TSHA-102 gene therapy for Rett syndrome, implying a high perceived risk and reliance on successful clinical and regulatory outcomes to sustain its current premium. Investors should assess whether the future path for TSHA-102 justifies this high valuation or if any setbacks could lead to a multiple reset.
Taysha Gene Therapies, Inc. Q2 2026 Earnings Call Summary
Taysha Gene Therapies, Inc. (TSHA) released its Q2 2026 earnings call summary, highlighting the completion of dosing in key trials and anticipating top-line data in H1 2027. The company's strategic focus on developmental milestones and a strong safety profile are intended to support BLA submission and market access, with current cash reserves projected to last into H2 2028.
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies announced the completion of dosing for its REVEAL pivotal trial and ASPIRE trial for TSHA-102, a gene therapy candidate for Rett syndrome, with plans for a potential biologics license application submission. The company reported positive longer-term data from Part A of the REVEAL trial, showing significant developmental milestone gains and functional improvements across various domains. Despite a reported Grade 2 peripheral sensory neuropathy event in one patient, Taysha emphasized that TSHA-102 has been generally well tolerated and is advancing manufacturing and commercial preparations, anticipating cash resources to fund operations into the second half of 2028.
Taysha Gene Therapies, Inc. Stock 12‑Month Price Target Raised to $13.33, Implies 100% Upside
Taysha Gene Therapies, Inc.'s stock has seen its average 12-month price target increased to $13.33, up from $13.25, according to 12 analysts. This new target implies a potential 100% upside based on the Aug. 11 closing price. The consensus rating for the stock remains a "Buy" with all 12 analysts recommending it.
Renaissance Technologies LLC Purchases 242,103 Shares of Taysha Gene Therapies, Inc. $TSHA
Renaissance Technologies LLC significantly increased its stake in Taysha Gene Therapies (NASDAQ: TSHA) by 141.5% in the first quarter, acquiring an additional 242,103 shares. This brings their total holding to 413,203 shares valued at approximately $1.85 million. Despite this institutional confidence and a consensus "Buy" rating from analysts, Taysha Gene Therapies missed its quarterly EPS expectations.
Taysha Gene Therapies Q2 Earnings Call Highlights
Taysha Gene Therapies announced the completion of dosing in its REVEAL pivotal trial and ASPIRE study for TSHA-102, a gene therapy for Rett syndrome, with an interim analysis potentially accelerating a BLA filing to early 2027. Long-term data from Part A showed all 12 patients achieved developmental milestones at 12 months, significantly exceeding the FDA's 33% efficacy threshold. Despite a wider Q2 net loss of $46.6 million due to increased development costs, the company's $455.4 million cash position is projected to fund operations into the second half of 2028.
Earnings call transcript: Taysha Gene Therapies misses Q2 2026 EPS forecast
Taysha Gene Therapies (TSHA) reported a wider second-quarter loss for 2026, missing Wall Street's EPS forecast by $0.01, with shares falling 6.44% in after-hours trading. Despite the earnings miss, the company highlighted significant clinical progress with its lead Rett syndrome gene therapy, TSHA-102, completing dosing in two pivotal trials and maintaining a cash runway into the second half of 2028. Management focused on ongoing clinical development, manufacturing readiness, and commercialization plans, addressing questions on a mild treatment-related adverse event and the innovative endpoint strategy for regulatory approval.
Taysha Gene Therapies Q2 Results: Net Loss Widens To $46.6 Million
Taysha Gene Therapies reported a widening net loss of $46.6 million in Q2 2026, missing EPS estimates, primarily due to increased R&D spending on its lead candidate TSHA-102 for Rett syndrome. Despite the losses, the company strengthened its cash reserves to $455.4 million through equity financing, expected to fund operations into the second half of 2028. Taysha also completed dosing in its pivotal REVEAL and ASPIRE trials, with top-line results anticipated in the first half of 2027, and secured a commercial manufacturing partnership with Catalent.
Earnings Flash (TSHA) Taysha Gene Therapies Posts Q2 Loss of $0.13, vs. FactSet Est of $0.11 Loss
Taysha Gene Therapies (TSHA) reported a Q2 loss of $0.13 per share, which is wider than the FactSet estimate of a $0.11 loss. This financial update indicates that the company's performance for the second quarter of 2026 fell short of analyst expectations. The article also provides a company profile, outlining its focus on gene therapies for central nervous system diseases.
Taysha Gene Therapies Q2 net loss widens on higher R&D costs
Taysha Gene Therapies reported a widening net loss in the second quarter due to increased research and development costs. The article, sourced from Reuters and provided via TradingView, indicates that the full details are available to subscribers.
Taysha Gene Therapies (NASDAQ:TSHA) Posts Quarterly Earnings Results, Misses Estimates By $0.02 EPS
Taysha Gene Therapies (NASDAQ:TSHA) reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Despite this, the stock rose 5.3% to $6.71, supported by strong liquidity and significant institutional ownership. Analyst sentiment is generally positive, with an average "Buy" rating and a $12.77 price target.
Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Taysha Gene Therapies announced its second-quarter 2026 financial results, highlighting the completion of dosing in its pivotal REVEAL and ASPIRE trials for TSHA-102 in Rett syndrome. The company expects to report topline data and FDA feedback on the BLA submission pathway in the first half of 2027, bolstered by positive longer-term data and a strengthened cash runway into 2H 2028 from a recent $230 million offering. TSHA-102 continues to show a generally well-tolerated safety profile and broad functional gains.
Taysha Gene Therapies (TSHA) Is Up 10.2% After Securing Long-Term TSHA-102 Manufacturing Capacity
Taysha Gene Therapies (TSHA) saw a 10.2% stock increase after announcing a commercial supply agreement with Catalent for the manufacturing of TSHA-102, its investigational Rett syndrome gene therapy. This deal secures long-term GMP capacity, preparing Taysha for potential commercialization, though the company remains loss-making and relies on upcoming clinical data and regulatory decisions for value inflection. Analysts project significant revenue growth and a shift to profitability by 2029 for Taysha.
Taysha Gene faces earnings test as Rett therapy advances
Taysha Gene Therapies Inc. (TSHA) is set to report its second-quarter earnings, with investor focus primarily on the progress of its lead gene therapy candidate, TSHA-102, for Rett syndrome, rather than its financial results. Analysts expect a loss of $0.12 per share on $300,000 in revenue, and while the company is pre-commercial and unprofitable, Wall Street maintains a "strong buy" rating with a significant upside potential. Key areas for investors include updates on TSHA-102's clinical development, patient enrollment, trial timelines, safety data, and the company's cash burn and runway.
Taysha Gene faces earnings test as Rett therapy advances
Taysha Gene Therapies Inc. is reporting second-quarter earnings, with focus primarily on the progress of its lead gene therapy candidate, TSHA-102, for Rett syndrome, rather than its financial results. Analysts expect continued losses but maintain a "strong buy" rating, anticipating significant upside. Investors will be keen on updates regarding clinical trial timelines, patient enrollment, safety data, and the company's cash burn and commercial strategy for TSHA-102.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Taysha Gene Therapies announced an inducement grant to a new employee on August 3, 2026, comprising restricted stock units for 144,000 shares and an option to purchase 92,400 shares. This grant was made under the company's 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4), to attract new talent. The RSUs and stock options have multi-year vesting schedules, subject to continued employment, with the stock option's exercise price set at the closing price on the grant date.
Taysha Gene Therapies, Inc. (TSHA): Investor Outlook Reveals A Potential 108.99% Upside
Taysha Gene Therapies, Inc. (TSHA), a clinical-stage biotechnology firm, is attracting investor attention due to its promising pipeline in adeno-associated virus-based gene therapies for severe monogenic central nervous system diseases. Despite current negative financial metrics typical of developmental biotech firms, analysts project a potential upside of 108.99% based on an average target price of $13.25, with unanimous buy ratings. The company's strategic collaborations and robust technical indicators suggest a stable outlook, offering a high-risk, high-reward opportunity for investors willing to navigate the biotechnology sector's inherent volatility.
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies and Catalent have expanded their strategic partnership to include commercial manufacturing support for TSHA-102, Taysha's investigational gene therapy for Rett syndrome. This agreement secures long-term manufacturing capacity and a scalable supply framework, with Catalent providing GMP manufacturing at its FDA-licensed facility in Harmans, Maryland. The collaboration aims to ensure readiness for a potential commercial launch and future demand for TSHA-102, addressing the critical need for a disease-modifying therapy for Rett syndrome.
Manufacturing deal prepares Rett gene therapy for potential U.S. launch
Taysha Gene Therapies has announced a commercial supply agreement with Catalent to prepare for the potential U.S. launch of TSHA-102, an experimental gene therapy for Rett syndrome. Catalent will serve as the primary commercial manufacturer if TSHA-102 receives FDA approval, building on their existing partnership since 2020. This agreement is a critical step in Taysha's launch readiness strategy as TSHA-102 continues in pivotal clinical testing.
Taysha Gene Therapies to Release Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 11
Taysha Gene Therapies, a clinical-stage biotechnology company, announced it will release its second-quarter 2026 financial results and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. The webcast will be accessible on the company's website. Taysha Gene Therapies is focused on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system, with its lead clinical program TSHA-102 targeting Rett syndrome.
Taysha Sets Aug. 11 Webcast on Rare-Disease Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) will report its second-quarter 2026 financial results and host a corporate update conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. The company, focused on AAV-based gene therapies for severe monogenic CNS diseases, will make the live and archived webcast accessible via the Events and Presentations page of its investor relations website. Taysha's lead clinical program, TSHA-102, is in development for Rett syndrome, a rare neurodevelopmental disorder.
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies and Catalent have expanded their strategic partnership to include future commercial manufacturing support for TSHA-102, Taysha's investigational gene therapy for Rett syndrome. This commercial supply agreement positions Catalent as Taysha's primary manufacturer post-FDA approval, leveraging Catalent's gene therapy expertise and manufacturing capabilities. The collaboration aims to ensure long-term manufacturing capacity and a scalable supply framework for the potential commercial launch of TSHA-102, which is currently in pivotal development.
Taysha Gene Therapies to Release Second Quarter 2026
Taysha Gene Therapies announced it will report its second-quarter 2026 financial results and host a conference call and webcast on Tuesday, August 11, 2026, at 4:30 PM Eastern Time. The clinical-stage biotechnology company focuses on developing AAV-based gene therapies for severe monogenic diseases of the central nervous system, with its lead program TSHA-102 targeting Rett syndrome. The company aims to address unmet medical needs and improve patient lives through its experienced management team and advanced gene therapy development.
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies and Catalent have expanded their strategic partnership to include commercial manufacturing support for TSHA-102, Taysha’s gene therapy for Rett syndrome. Catalent will serve as the primary commercial manufacturer following potential FDA approval, ensuring long-term capacity and a scalable supply. This agreement builds on their existing collaboration since 2020 and aims to meet future demand for the therapy.
Taysha secures commercial manufacturing deal with Catalent
Taysha Gene Therapies announced a commercial supply agreement with Catalent, Inc. for TSHA-102, an investigational gene therapy for Rett syndrome. Catalent will serve as Taysha’s primary commercial manufacturer after potential U.S. FDA approval, providing GMP manufacturing and commercial supply from its facility in Harmans, Maryland. This agreement is a critical part of Taysha's launch readiness strategy for TSHA-102, which is currently in pivotal development for the rare neurodevelopmental disorder.
Taysha’s Rett Gene Therapy Gets a Future Commercial Manufacturer
Taysha Gene Therapies and Catalent have expanded their partnership with a commercial supply agreement for TSHA-102, an investigational gene therapy for Rett syndrome. Under the agreement, Catalent will serve as the primary commercial manufacturer for TSHA-102 following potential U.S. FDA approval, leveraging its FDA-licensed gene therapy facility in Harmans, Maryland. This deal secures long-term GMP manufacturing capacity and a scalable supply framework, with BLA-enabling Process Performance Qualification activities for TSHA-102 already underway to align manufacturing readiness with a future commercial launch.
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
Taysha Gene Therapies and Catalent have announced an expanded strategic partnership, including a commercial supply agreement for TSHA-102, Taysha’s gene therapy for Rett syndrome. Catalent will serve as the primary commercial manufacturer for TSHA-102 following potential FDA approval, leveraging its expertise and facilities in Maryland. This collaboration aims to ensure long-term commercial manufacturing capacity and a scalable supply framework to support the potential launch and future demand for the gene therapy.
Catalent, Taysha extend AAV-based gene therapy partnership
Taysha Gene Therapies and Catalent have announced a commercial supply agreement for TSHA-102, Taysha’s investigational gene therapy for Rett syndrome. This agreement extends their partnership, securing long-term manufacturing capacity and a scalable supply framework for TSHA-102 after potential FDA approval. Catalent will provide GMP manufacturing from its facility in Harmans, Maryland, supporting the potential commercial launch and future demand for the therapy.
Taysha Gene Therapies Inc (TSHA) Institutional Confidence
Taysha Gene Therapies Inc (TSHA) has an institutional shareholding score of 10.00, ranking 1st in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 100.06%, showing a 1.93% increase quarter-over-quarter. Steven Cohen is the largest institutional shareholder, holding 358.26K shares.
Taysha Gene Therapies Inc (TSHA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Taysha Gene Therapies Inc (TSHA), detailing its current valuation score of 8.53, ranking 113 out of 384 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -15.60, noting its position relative to recent highs and lows. The analysis also indicates that P/B, P/S, and P/CF relevant data have not yet been disclosed by the company.
Time To Take A Look At Taysha: Rett Syndrome Gene Therapy Trial On Track For Key Interim Analysis
Taysha Gene Therapies is advancing its gene therapy trial for Rett syndrome, a rare neurodevelopmental disorder caused by MECP2 gene mutations, towards a key interim analysis. The article highlights that Rett syndrome primarily affects females, with 6,000-9,000 patients in the US, and notes that Acadia Pharma's Daybue is currently the only FDA-approved treatment. Full access to the article is restricted to RTT Biotech Investor and Intelligent Investor subscribers.
Taysha Gene Therapies, Inc. Revenue Breakdown – NASDAQ:TSHA
This article details Taysha Gene Therapies, Inc.'s revenue breakdown for the last year. The company generated $9.77 million USD, with its Gene Therapy segment being the top performer. All reported revenue originated from the United States.
Taysha Gene Therapies Inc (TSHA) Cash Flow
This article provides Taysha Gene Therapies Inc's (TSHA) cash flow statements, including operating, investing, and financing activities, across numerous quarters from FY2020Q3 to FY2026Q1. It details line items such as net income, non-cash items, and changes in working capital. The piece also includes a FAQ section defining different types of cash flow and their significance for TSHA's financial analysis.
TSHA|Taysha Gene Therapies Inc|Price:5.520|Chg%:-0.310
Taysha Gene Therapies Inc. (TSHA) currently has a TradingKey Stock Score of 7.22/10, indicating healthy fundamentals and high growth potential, despite a recent weak stock market performance. The company, focused on AAV-based gene therapies for severe monogenic CNS diseases, is considered fairly valued and has high institutional ownership. Analysts have rated TSHA as a "Buy" with a target price of $13.15, suggesting a 125.62% upside.
Taysha Gene Therapies, Inc. (TSHA) Stock Analysis: Uncovering a Potential 125% Upside in the Biotech Sector
Taysha Gene Therapies (TSHA) is a Dallas-based biotech company specializing in AAV-based gene therapies for severe central nervous system diseases. Analysts project a potential upside of 125.62%, with an average target price of $13.15, despite the company's current operating losses and negative free cash flow characteristic of its developmental stage. The company's robust therapeutic pipeline and strong analyst confidence make it an intriguing, high-risk, high-reward opportunity for investors in the biotech sector.
Taysha Gene Therapies posts corporate deck highlighting TSHA-102 gene therapy program for Rett syndrome
Taysha Gene Therapies has released a corporate deck providing updates on its TSHA-102 gene therapy program for Rett syndrome. The company anticipates a registration strategy for TSHA-102, a one-time intrathecal AAV9 gene therapy. The REVEAL pivotal trial showed a 100% response rate in Part A, with a 6-month interim readout expected in 1H 2027, and FDA alignment suggests a potential BLA submission based on interim analysis.
Taysha Gene Therapies president sells $1.25m in stock By Investing.com
Taysha Gene Therapies' President and Head of Research & Development, Nagendran Sukumar, sold 200,000 shares of company stock for $1.25 million on July 10, 2026, as part of a pre-planned trading strategy. This sale occurred while TSHA shares have surged 149% over the past year, though InvestingPro analysis suggests the stock is currently overvalued. The company also recently announced a $200 million stock offering and will present new data on its TSHA-102 gene therapy for Rett syndrome.
Taysha Gene Therapies president sells $1.25m in stock
The President and Head of Research & Development at Taysha Gene Therapies, Nagendran Sukumar, sold 200,000 shares of company stock for $1.25 million on July 10, 2026. This transaction was part of a pre-arranged 10b5-1 trading plan. The sale follows a significant 149% surge in TSHA shares over the past year, though InvestingPro analysis suggests the stock is currently overvalued.
Insider Sell: Sukumar Nagendran Sells 200,000 Shares of Taysha Gene Therapies Inc (TSHA)
Sukumar Nagendran, President and Head of Research and Development at Taysha Gene Therapies Inc (TSHA), sold 200,000 shares of the company on July 10, 2026. This transaction increased his total sales over the past year to 1,343,276 shares, with no purchases. The stock is currently trading at $6.24 per share, significantly above its estimated GF Value of $0.69, indicating it is overvalued.
